07.18.18
NeuroCog Trials (NCT) announced a major appointment on their scientific leadership team. Dr. Kathleen Anne Welsh-Bohmer, a specialist in Alzheimer’s Disease research, has joined as the vice president of Neurodegenerative Disorders. In her new role she will lead the development of new technology and tools to support customers conducting clinical trials for dementia and other cognitive disorders.
Having dedicated more than 25 years to research surrounding neurodegenerative disorders that occur later in life, Dr. Welsh-Bohmer is a Professor of Psychiatry and Neurology at Duke University. Her work includes neuropsychology leadership in the Takeda Pharmaceutical’s TOMMORROW STUDY, the largest, industry-sponsored, Phase 3 clinical trial of its kind with a focus on the secondary prevention of mild cognitive impairment (MCI) due to AD. The methods her team developed for this study filled an information void and led to the validation of a genetic biomarker that will help to accelerate global clinical trials in AD prevention.
Dr. Richard Keefe, co-founder and chief executive officer of NeuroCog Trials, said, “Dr. Welsh-Bohmer has been an esteemed colleague and partner on several global clinical trials and I am delighted to have her join NCT as we continue to offer pharmaceutical companies development solutions to address this enormous unmet need. Seen as one of the most challenging areas of drug development, the Alzheimer’s treatment and prevention landscape requires quickly evolving regulatory guidance and disruptive therapeutic approaches. As one of the true leaders in the AD scientific research field, Dr. Welsh-Bohmer brings that expertise to our team and our clients’ projects.”
Having dedicated more than 25 years to research surrounding neurodegenerative disorders that occur later in life, Dr. Welsh-Bohmer is a Professor of Psychiatry and Neurology at Duke University. Her work includes neuropsychology leadership in the Takeda Pharmaceutical’s TOMMORROW STUDY, the largest, industry-sponsored, Phase 3 clinical trial of its kind with a focus on the secondary prevention of mild cognitive impairment (MCI) due to AD. The methods her team developed for this study filled an information void and led to the validation of a genetic biomarker that will help to accelerate global clinical trials in AD prevention.
Dr. Richard Keefe, co-founder and chief executive officer of NeuroCog Trials, said, “Dr. Welsh-Bohmer has been an esteemed colleague and partner on several global clinical trials and I am delighted to have her join NCT as we continue to offer pharmaceutical companies development solutions to address this enormous unmet need. Seen as one of the most challenging areas of drug development, the Alzheimer’s treatment and prevention landscape requires quickly evolving regulatory guidance and disruptive therapeutic approaches. As one of the true leaders in the AD scientific research field, Dr. Welsh-Bohmer brings that expertise to our team and our clients’ projects.”